Analysis of Factor-VIU-related antigen (vW) in normal plasma by crossed immunoelectrophoresis reveals an asymmetric pattern indicative of molecular heterogeneity. This asymmetric pattern apparently results from the presence of multiple molecular forms of vWAg with distinct, though partially overlapping, mobilities on crossed immunoelectrophoresis. Evidence for this conclusion has been obtained by separating these forms, one from another, utilizing cryoprecipitation, agarose gel chromatography, and ionexchange chromatography.
Molecules expressing Factor-VIII-related antigen (von Willebrand's antigen, vWAg) are decreased in the plasmas of individuals with typical von Willebrand's disease though present in normal amounts in plasmas from individuals with hemophilia A. The concentration of plasma vWAg in normal plasmas correlates well with plasma Factor VIII procoagulant activity (VIII) and with the activity of a plasma factor required for platelet adhesiveness and ristocetin-induced platelet aggregation (von Willebrand's Factor, vWF) (1, 2) . Both of these activities copurify with vWAg under a variety of conditions, suggesting that they reside on the vWAg molecule (3,4y.-However, additional studies have suggested antigenic differences between molecules responsible for procoagulant activity and those expressing vWAg (5) . In addiffon, the two can be separated to various degrees by agarose gel chromatography at high strength (6) .
We now report that molecules expressing vWAg are present in normal human plasma in several different forms when analyzed by crossed immunoelectrophoresis. These forms can be separated one from another by cryoprecipitation, agarose gel chromatography at physiologic salt concentrations, and anion exchange chromatography. The relative distribution of vWAg in plasmas from individuals with liver disease and disseminated intravascular coagulation often differs from that seen in normal individuals, indicating that as yet unidentified in vio events influence the generation of different VWAg forms.
MATERIALS AND METHODS
Blood drawn with plastic syringes was routinely collected into citrate-phosphate-dextrose anticoagulant containing sufficient phenylmethylsulfonyl fluoride (PMSF) and Trasylol (Aprotonin, FBA Pharmaceuticals) to give a final concentration of 1 mM and 10 kallikrein inactivator units/ml, respectively. In some experiments, benzamidine, 0.02 M, instead of PMSF, or e-aminocaproic acid, 0.2 M, instead of Trasylol was used with similar results. Platelet-poor plasma was prepared by centrifugation of blood at 1500 X g for 15 min followed by repeat centrifugation at 65,000 X g for 45 min. Plasma for preparation of cryoprecipitate was snap-frozen with liquid nitrogen and stored at -70°. Cryoprecipitate was prepared by allowing the frozen plasma to thaw at 0°in an ice water-bath. The precipitate was collected by centrifugation at 27,000 X g for 20 min. Cryoprecipitate from 50 to 100 ml of plasma was dissolved in 2 ml of barbital saline buffer (0.01 M barbital sodium, 0.015 M barbital, 0.125 M sodium chloride, pH 7.5).
Anion exchange chromatography of whole plasma or unconcentrated cryosupernatant plasma was performed in the following manner. Plasmas were treated with 1 mM DFP (diisopropylfluorophosphate) and then absorbed with aluminum hydroxide (Rehsorptar, Armour Pharmaceuticals, Kankakee, Ill.). One part of aluminum hydroxide was mixed with 10 parts of plasma and incubated with gentle stirring for 15 min at 22-25°. The aluminum hydroxide was removed by centrifugation at 17,000 Xg for 10 min. The plasma (100-400 ml) was then adjusted to a conductance between 1.5 and 6.0 mmho (mS), depending on the batch of DEAE-agarose (Bio-Rad) to be used, by dialysis against water using a Bio-Fiber device. Additional PMSF and Trasylol were added to a concentration of 1 mM and 10 units/ml, respectively; and the plasma was again centrifuged at 65,000 X g for 45 min. Plasma was then applied to a column of DEAE-agarose which had been equilibrated with 0.01 M Tris, pH 7.5 buffer (Tris buffer) adjusted to a conductance of between 1.5 mm diameter wells. Column samples were usually assayed in the eluting buffer. Dialysis of samples from DEAE-agarose chromatography into the higher ionic strength buffer used for agarose gel chromatography did not appreciably effect the results. Evan's blue dye was added to plasma samples, or Evan's blue dye mixed with 20% bovine serum albumin was added to column samples, as a marker. The first dimension (7.7 cm) was run in 0.9% weight/volume agarose (Van Waters and Rogers Scientific) in 0.025 M barbital buffer, pH 9.5, poured to a thickness of 1.5 mm, at a constant current of 3.75 mA per slide. Electrophoresis was continued until the marker dye migrated 6.5 cm (approximately 3 hr). Electrophoresis in the second dimension (5.1 cm) was carried out at a constant current of 5 mA per slide for 16 hr. Antiserum to vWAg was prepared as described previously (7) . It precipitated with vWAg and inactivated Factor VIII precoagulant activity and von Willebrand Factor activity. An ammonium-sulfate-precipitated globulin fraction of the antiserum was used at a final concentration of 0.06-0.08 mg/ml (7). Slides were washed, dried, and stained-with Coomassie blue as previously described (7).
RESULTS
Analysis of normal plasma vWAg by crossed immunoelectrophoresis reveals a characteristic asymmetric pattern (Figs. 1 and 2) indicative of heterogeneity. The following experiments demonstrate that this asymmetric pattern is due to the presence of multiple molecular forms of vWAg, with different mobilities on electrophoresis in agarose gel. First, cryoprecipitation was found to precipitate predominantly slowly moving forms of vWAg, leaving faster moving forms in the cryosupernatant plasma (Fig. 1, slides 5, 6 , and 7).
Second, 4% agarose gel chromatography of cryoprecipitated vWAg resolved it into multiple forms. Though vWAg was present in the void volume it also eluted in later fractions. When fractions from 1.0 to 2.0 Vo were analyzed by crossed immunoelectrophoresis it was found that at least four different forms had been separated to various degrees one from the other (Fig. 2) . Evidence that these forms were not in equilibrium one with another but did represent stable and distinct entities was obtained by mixing the form eluting at 1.04 Vo with that eluting at 1.2 Vo and analyzing the mixture by crossed immunoelectrophoresis. Two peaks are seen, each with the approximate mobility of the individual components analyzed separately ( Fig. 2A, Slide 7) . Though the precise position of different forms varied somewhat in five different column runs, utilizing five different cryoprecipitates, in each case those forms with faster mobility on crossed immunoelectrophoresis eluted after those forms with slower mobility.
Ion exchange chromatography on DEAE-agarose of cryosupernatant plasma allowed partial resolution of two fastmoving forms of vWAg (see Fig. 1 , Slide. 8), though on occasion only the fastest moving was present. These forms were further resolved by agarose gel chromatography. In a typical experiment, one form eluted at 1.2 Vo and the second at 1.82 Vo (see Fig. 2 ). The slower moving of the two forms was also present in most cryoprecipitates, the faster usually not. Thus a total of at least five different forms of vWAg were identified.
Third, evidence that the different vWAg forms exist in plasma and are not simply artifacts of the cryoprecipitation process was provided by chromatographic analysis of whole plasma on DEAE-agarose. Forms with faster mobility on crossed immunoelectrophoresis eluted at a lower conductance and those with slower mobility eluted later (Fig. 2B) . (Fig. 1, Slide 5) . DISCUSSION These studies demonstrate that vWAg exists in normal human plasma not as a single species, but rather as at least five distinct forms with different mobilities on crossed immunoelectrophoresis. The differing behavior of these forms under a variety of physical conditions further distinguishes them one from another. The slow mobility forms are separated from those with rapid mobility by cryoprecipitation, the latter remaining largely in the supernatant. Those with faster mobility elute from DEAE-agarose columns at lower conductance than the slower forms, suggesting that charge differences may exist between them and may account in part for the observed differences in behavior on crossed immunoelectrophoresis. Size differences are suggested by the behavior of vWAg forms on agarose chromatography. The slowest forms are recovered in, or just after, the void volume, whereas the fastest forms elute considerably later. Variable interaction of different forms with the agarose on a basis other than size may be responsible for this behavior, however (8) . The existence of the vWAg forms as independent molecular entities is supported by the absence of equi.p librium redistribution to a symmetrical pattern following mixing of forms which elute at different positions from the columns. This ability to clearly resolve forms of differing mobilities indicates that the asymmetric pattern seen in whole plasma is caused by the presence of a number of sets of vWAg molecules with overlapping mobilities. Crossed immunoelectrophoretic analysis of vWAg in plasma, serum, and plasma fractions. The anode is to the right in the first dimension and at the top in the second dimension. As a marker Evan's blue dye or Evan's blue dye and bovine serum albumin were mixed with the samples and electrophoresed 6.5 cm in the first dimension. Slide 1. Typical normal plasma. Marked asymmetry, indicative of heterogeneity, is evident. Compare with Fig. 2A , Slides 2-6 in which five vWAg forms with differing mobilities in agarose gel electrophoresis have been separated from one another and give symmetrical patterns. Slide 2. Typical normal serum. Blood (from which plasma analyzed in Slide 1 was also obtained) was allowed to clot for 2 hr at 370 in the presence of Trasylol, 100 units/ml. A moderate shift to faster vWAg forms is seen. Slide 3. Plasma from an individual with disseminated intravascular coagulation. A marked increase in vWAg of intermediate mobility is seen. Slide 4. Plasma from an individual with liver disease. A marked increase in the forms of fast mobility is observed. In other cases of liver disease, an increase in forms with slower or intermediate mobility was also seen. Slide 5. Plasma from an individual with Hemophilia A. The pattern is essentially the same as that seen in normal individuals. Retention of vWAg at the origin occurred with a minority of normal and pathologic plasmas. Slide 6. Cryoprecipitate prepared from normal plasmas. Slower vWAg forms predominate. Slide 7. Supernatant plasma remaining after cryoprecipitation (cryosupernatant). The supernatant plasma was concentrated on a Bio-Fiber device prior to a crossed immunoelectrophoretic analysis. Only the faster moving forms are detectable. Slide 8. Cryosupernatant, absorbed to DEAE-agarose and eluted with a sodium chloride gradient. Two fast-moving forms are seen. These were further resolved by agarose gel chromatography (see Fig. 2 , Slides 5 and 6).
The relationship of the different VWAg forms to Factor VIII procoagulant activity and von Willebrand's Factor activity is as yet unclear. Factor VIII procoagulant activity: vWAg ratios are often decreased in liver disease (9) 
